Akoya Biosciences (AKYA) announced its reagent product roadmap, featuring new ultrahigh-plex neurobiology panels for human and mouse applications. Building on the success of the Human IO60 and Mouse FFPE IO panels, which debuted at the Society for Immunotherapy of Cancer Annual Meeting in November 2024, this roadmap represents the next step in the company’s mission to provide cutting-edge tools for advancing research across multiple market including oncology, inflammatory disease and neurobiology. Transforming Spatial Proteomics with IO60: Since its launch, the PhenoCode Discovery IO60 panel has been celebrated by key opinion leaders and contract research organizations for its ability to generate deep insights into immune landscapes and tumor-immune interactions. Ultrahigh-Plex Neurobiology Panels: A Major Step Forward: Expanding on the success of IO60, the company is set to release PhenoCode Human and Mouse FFPE Neurobiology panels at the end of Q1 and Q2 2025 respectively.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Akoya Biosciences selects Argonaut Manufacturing as IVD manufacturing partner
- Quanterix price target lowered to $11 from $15 at TD Cowen
- Akoya Biosciences downgraded to Hold from Buy at Canaccord
- Quanterix to acquire Akoya Biosciences in an all-stock transaction
- Akoya Biosciences, NeraCare enter exclusive global license agreement